LENZ Misses Estimates Despite VIZZs Strong Launch

LENZ Therapeutics (LENZ) reported mixed results for fiscal 2025 Q4, with revenue flat at $1.59 million and a net loss of $35.90 million. The company missed both revenue and earnings estimates, with GAAP EPS at -$1.16 (missing by $0.26) and revenue underperforming by $1.5 million. Management highlighted strong early demand for its flagship product VIZZ but acknowledged the need for operational efficiency to improve cash flow.

Revenue

LENZ Therapeutics reported total revenue of $1.59 million in Q4 2025, unchanged from the prior year period. This figure reflects the commercial launch of VIZZ in October 2025, which generated $1.6 million in product revenue during its first quarter.

Earnings/Net Income

The company maintained an EPS of $-1.15 in Q4 2025, with a net loss widening to $35.90 million—unchanged year-over-year. While this marked a new fiscal Q4 net income record, the persistent losses highlight ongoing financial pressures despite early product traction.

Price Action

LENZ’s stock price declined sharply post-earnings, falling 13.75% in a single trading day, 27.76% over the week, and 22.09% month-to-date.

Post-Earnings Price Action Review

The strategy of buying LENZ shares 30 days after quarterly reports over the past three years underperformed dramatically, returning -55.28% compared to a 43.94% benchmark gain. This resulted in an excess return of -99.23% and a CAGR of -18.36%, underscoring investor skepticism about the company’s growth trajectory.

CEO Commentary

CEO Evert Schimmelpennink emphasized VIZZ’s clinical efficacy and rapid patient adoption, with 45,000 prescriptions filled through Q1 2026. Strategic priorities include scaling the sales force to 117 reps, enhancing physician education, and expanding DTC campaigns. The company aims to address 128 million presbyopes in the U.S. with its differentiated once-daily eye drop.

Guidance

LENZ expects its $292.3 million cash reserves to fund operations until post-launch positive cash flow.

Additional News

LENZ Therapeutics launched VIZZ in October 2025, achieving 45,000 prescriptions by Q1 2026 and 10,000 prescribers. The company expanded its sales force and launched a DTC campaign featuring Sarah Jessica Parker, driving a 10x increase in website traffic. Management also announced plans to scale national TV advertising in Q2 2026 to boost awareness.